HHS to Launch Campaign Promoting Wearable Devices

June 26, 2025

Reading Time : 2 min

On June 24, 2025, in a hearing before the U.S. House of Representatives Committee on Energy and Commerce, the Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr. revealed that his department plans to soon launch an advertising campaign encouraging Americans to use wearable health devices. The campaign is set to be “one of the biggest advertising campaigns in HHS history.”

As described by Secretary Kennedy, wearables enable individuals to take responsibility over their health and make informed decisions: “People can take control over their own health. . . They can see what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it. And they can begin to make good judgments about their diet, about their physical activity, about the way that they live their lives,” Secretary Kennedy said.

Secretary Kennedy went on to state that he has observed the positive impact of wearables (like glucose meters) for weight loss and diabetes management. He noted that the wearables were cost-effective—contrasting the expense of a wearable with the cost of a drug such as Ozempic—and said that the department was “exploring ways of making sure that those costs can be paid for.”

“We think that wearables are a key to the MAHA agenda—Making America Healthy Again, and . . . my vision is that every American is wearing a wearable within four years,” added Secretary Kennedy.

This announcement reflects the growing role of digital and wearable health tools in U.S. public health strategy. However, current law draws a significant distinction between wearables used only for “wellness” and wearables that are intended for use in health care decision-making. The latter are generally regulated by the Food and Drug Administration (FDA) as medical devices (or, in some cases, a certain software function available through a wearable is regulated as a medical device). Typically, medical devices need FDA clearance or approval to be covered by federal health programs. Wearable devices also raise data protection and privacy concerns, as they collect large volumes of personal and sensitive health data, which may be shared by third party apps and services. Connectivity and interoperability will also be important considerations, to the extent the objective is for consumers to be able to share this data with their providers. One of the core impediments to leveraging health metric data from wearables has been the lack of consistent approaches to incorporate such data into a patient’s health care records and treatment.

Nevertheless, as the Secretary’s comments before the Energy and Commerce Committee and the House Ways and Means Committee hearing on digital health this week underscore, digital health continues to be an active area of interest for policy-makers that resonates with the MAHA agenda.

Share This Insight

Previous Entries

Eye on FDA

April 8, 2026

On March 31, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting information and public comment (RFI) on the use of digital health technologies (DHTs) in clinical investigations for drugs and biological products. To inform potential FDA activities in this area, the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) are seeking feedback to better understand the opportunities and challenges associated with using these innovative technologies in clinical investigations.

...

Read More

Eye on FDA

April 1, 2026

On March 30, 2026, the Food and Drug Administration (FDA) published a final guidance entitled “Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle.” The guidance provides updated recommendations to industry and FDA on how and when voluntary patient preference information (PPI) may be considered by FDA staff in decision making relating to devices. PPI is not required for FDA’s consideration as part of FDA decision making, but FDA may find it valuable to consider patient viewpoints when the information meets applicable legal requirements. In addition, FDA encourages industry and other interested parties to consider patient experience data in device development and evaluation, including data relating to patient preferences for outcomes and treatments. FDA acknowledges that patient perspective and personal experiences can help FDA evaluate the benefit-risk profile of certain devices throughout the total product life cycle.

...

Read More

Eye on FDA

March 24, 2026

On March 20, 2026, the Food and Drug Administration (FDA) announced the agency will hold a public hearing on the Commissioner’s National Priority Voucher (CNPV) Pilot Program, with a Federal Register notice soliciting public comment and scheduling a public hearing for June 12, 2026. As previously noted here and here, the program was announced in June 2025 for the purpose of providing select sponsors with a nontransferable voucher for enhanced engagement with FDA and expedited review for drugs and biologics supporting one or more critical national health priorities, while maintaining adherence to the law’s rigorous safety and effectiveness standards. The national health priorities include public health crisis response, innovative breakthrough therapies, large unmet medical needs, onshoring and supply chain resilience initiatives, and affordability improvements. To date, FDA has issued 18 Commissioner’s National Priority vouchers and approved four products to receive these vouchers, including two oncology drugs 44 and 55 days after filing.

...

Read More

Eye on FDA

March 20, 2026

On March 18, 2026, the Food and Drug Administration (FDA) issued draft guidance entitled “General Considerations for the Use of New Approach Methodologies in Drug Development.” The guidance is meant to provide drug developers with a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The use of NAMs can improve predictive toxicology in humans and reduce reliance on animal testing.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.